INTELLIGENT BIO SOLUTIONS IN (INBS) Stock Fundamental Analysis
USA - NASDAQ:INBS - US36151G6008 - Common Stock
0.8205 USD
+0.01 (+1.69%)
Taking everything into account, INBS scores 2 out of 10 in our fundamental rating. INBS was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of INBS have multiple concerns. INBS has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year INBS has reported negative net income.
INBS had a negative operating cash flow in the past year.
In the past 5 years INBS always reported negative net income.
In the past 5 years INBS always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of INBS (-128.11%) is worse than 81.48% of its industry peers.
INBS has a worse Return On Equity (-352.75%) than 77.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -128.11% | ||
| ROE | -352.75% | ||
| ROIC | N/A |
ROA(3y)-101.5%
ROA(5y)-80.79%
ROE(3y)-251.51%
ROE(5y)-185.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 40.85%, INBS is doing worse than 65.08% of the companies in the same industry.
INBS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 40.85% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
INBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INBS has been increased compared to 1 year ago.
The number of shares outstanding for INBS has been increased compared to 5 years ago.
Compared to 1 year ago, INBS has an improved debt to assets ratio.
2.2 Solvency
INBS has an Altman-Z score of -13.75. This is a bad value and indicates that INBS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of INBS (-13.75) is worse than 82.54% of its industry peers.
INBS has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.07, INBS is doing good in the industry, outperforming 67.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.75 |
ROIC/WACCN/A
WACC8.55%
2.3 Liquidity
A Current Ratio of 0.77 indicates that INBS may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.77, INBS is doing worse than 91.01% of the companies in the same industry.
INBS has a Quick Ratio of 0.77. This is a bad value and indicates that INBS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.65, INBS is not doing good in the industry: 88.89% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.77 | ||
| Quick Ratio | 0.65 |
3. Growth
3.1 Past
INBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.76%, which is quite impressive.
INBS shows a decrease in Revenue. In the last year, the revenue decreased by -1.90%.
Measured over the past years, INBS shows a very strong growth in Revenue. The Revenue has been growing by 74.49% on average per year.
EPS 1Y (TTM)94.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.79%
Revenue 1Y (TTM)-1.9%
Revenue growth 3Y91.13%
Revenue growth 5Y74.49%
Sales Q2Q%15.92%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y128%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year126.26%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for INBS. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 2.30, the valuation of INBS can be described as very cheap.
Based on the Price/Forward Earnings ratio, INBS is valued cheaper than 100.00% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of INBS to the average of the S&P500 Index (33.72), we can say INBS is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 2.3 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
INBS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:INBS (11/12/2025, 10:10:53 AM)
0.8205
+0.01 (+1.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners7.94%
Inst Owner Change-2.61%
Ins Owners0.6%
Ins Owner Change0%
Market Cap7.45M
Revenue(TTM)3.05M
Net Income(TTM)-10.57M
Analysts85.71
Price Target12.24 (1391.77%)
Short Float %5.87%
Short Ratio1.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-79.63%
Min Revenue beat(2)-80.72%
Max Revenue beat(2)-78.54%
Revenue beat(4)0
Avg Revenue beat(4)-70.98%
Min Revenue beat(4)-80.72%
Max Revenue beat(4)-51.15%
Revenue beat(8)0
Avg Revenue beat(8)-51.21%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 2.3 | ||
| P/S | 2.44 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.49 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.08
EYN/A
EPS(NY)0.36
Fwd EY43.51%
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0.34
BVpS0.33
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -128.11% | ||
| ROE | -352.75% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 40.85% | ||
| FCFM | N/A |
ROA(3y)-101.5%
ROA(5y)-80.79%
ROE(3y)-251.51%
ROE(5y)-185.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 23.89% | ||
| Cap/Sales | 7.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.77 | ||
| Quick Ratio | 0.65 | ||
| Altman-Z | -13.75 |
F-Score3
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.79%
EPS Next Y128%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.9%
Revenue growth 3Y91.13%
Revenue growth 5Y74.49%
Sales Q2Q%15.92%
Revenue Next Year126.26%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.1%
OCF growth 3YN/A
OCF growth 5YN/A
INTELLIGENT BIO SOLUTIONS IN / INBS FAQ
Can you provide the ChartMill fundamental rating for INTELLIGENT BIO SOLUTIONS IN?
ChartMill assigns a fundamental rating of 2 / 10 to INBS.
What is the valuation status for INBS stock?
ChartMill assigns a valuation rating of 4 / 10 to INTELLIGENT BIO SOLUTIONS IN (INBS). This can be considered as Fairly Valued.
How profitable is INTELLIGENT BIO SOLUTIONS IN (INBS) stock?
INTELLIGENT BIO SOLUTIONS IN (INBS) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for INBS stock?
The Earnings per Share (EPS) of INTELLIGENT BIO SOLUTIONS IN (INBS) is expected to grow by 128% in the next year.